HYPAQUE-CYSTO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hypaque-cysto, and when can generic versions of Hypaque-cysto launch?
Hypaque-cysto is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in HYPAQUE-CYSTO is diatrizoate meglumine. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the diatrizoate meglumine profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for HYPAQUE-CYSTO?
- What are the global sales for HYPAQUE-CYSTO?
- What is Average Wholesale Price for HYPAQUE-CYSTO?
Summary for HYPAQUE-CYSTO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 38 |
| Clinical Trials: | 4 |
| Patent Applications: | 1,000 |
| DailyMed Link: | HYPAQUE-CYSTO at DailyMed |
Recent Clinical Trials for HYPAQUE-CYSTO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Institute of Liver and Biliary Sciences, India | N/A |
| Dartmouth-Hitchcock Medical Center | Phase 2 |
| Spectrum Pharmaceuticals, Inc | Phase 2 |
US Patents and Regulatory Information for HYPAQUE-CYSTO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | HYPAQUE-CYSTO | diatrizoate meglumine | SOLUTION;URETHRAL | 016403-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
